Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.

Abstract: The present disclosure generally provides compounds that antagonize certain T2R taste receptors, including related uses, methods, and compositions for the reduction of bitter taste and/or the enhancement of sweet taste. In certain aspects, the disclosure provides flavored articles or flavored compositions comprising such compounds, as well as uses of such compounds to reduce the bitter taste and/or enhance the sweet taste of such flavored articles or flavored compositions.

Abstract: A method, computer system, and a computer program product is provided for generating a detailed thumbnail and/or preview of a content. In one embodiment the technique comprises analyzing data obtained from a content and classifying it according to a plurality of specific types. A plurality of key information may be then extracted from the data according to the classification. A plurality of key-values are correlated to the plurality of key information so as to provide a plurality of key-value pairs. These pairs are consolidated accordingly to generate a thumbnail and/or a preview that at least renders the key information provided by the consolidated key-value pairs as a rendering.

Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Abstract: In an embodiment, a method (100) is described. The method comprises receiving (102) data corresponding to a plurality of radiographic imaging slices of a body. The method further comprises determining (104) a position of a needle inserted in the body. The determination is based on combining information from at least one of the radiographic imaging slices comprising an indication of a first portion of the needle outside the body and at least one other of the radiographic imaging slices comprising an indication of a second portion of the needle inside the body. A combined needle region is generated by merging data corresponding to a position of the first portion of the needle outside the body with data corresponding to a position of the second portion of the needle inside the body.

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.

Abstract: Here disclosed is a composite catalyst for methane cracking and a method of producing the composite catalyst.

Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Abstract: In one example, the present disclosure describes a device, computer-readable medium, and method for automatically learning and facilitating interaction routines involving at least one human participant. In one example, a method includes learning an interaction routine conducted between a human user and a second party, wherein the interaction routine comprises a series of prompts and responses designed to identify and deliver desired information, storing a template of the interaction routine based on the learning, wherein the template includes at least a portion of the series of prompts and responses, detecting, in the course of a new instance of the interaction routine, at least one prompt from the second party that requests a response from the human user, and using the template to provide a response to the prompt so that involvement of the human user in the new instance of the interaction routine is minimized.

Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.

Abstract: The present disclosure generally provides compounds that antagonize certain T2R taste receptors, including related uses, methods, and compositions for the reduction of bitter taste and/or the enhancement of sweet taste. In certain aspects, the disclosure provides flavored articles or flavored compositions comprising such compounds, as well as uses of such compounds to reduce the bitter taste and/or enhance the sweet taste of such flavored articles or flavored compositions.

Abstract: A computer transforms content of a composite table into structured data objects. The computer receives a composite table and identifying a data zone characterized by data columns, and a header zone. The computer identifies first header cells arranged coextensive with a single data column and second header cells arranged coextensive with a set of data columns. The computer generates a hierarchical representation of said header cells, based at least in part, on the header cell arrangements. The computer generates a revised table based on the hierarchical representation, with the first header cells identifying a data column and the second header cells identify a first header cell. The computer generates structured data objects representing the zones and being arranged based, at least in part, on the revised table and where the structured data objects are keyed to the first header cells.

Abstract: The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.

Abstract: A computer transforms content of a composite table into structured data objects. The computer receives a composite table and identifying a data zone characterized by data columns, and a header zone. The computer identifies first header cells arranged coextensive with a single data column and second header cells arranged coextensive with a set of data columns. The computer generates a hierarchical representation of said header cells, based at least in part, on the header cell arrangements. The computer generates a revised table based on the hierarchical representation, with the first header cells identifying a data column and the second header cells identify a first header cell. The computer generates structured data objects representing the zones and being arranged based, at least in part, on the revised table and where the structured data objects are keyed to the first header cells.

Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFN?, NECTIN2, and CSFIR. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.